Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder

Psychiatry and Clinical Neurosciences

Volumn 62, Issue 3, 2008, Pages 370-

  Nakaaki, Shutaro ^a   Murata, Yoshie ^a   Furukawa, Toshi A ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; OLANZAPINE; PAROXETINE; RISPERIDONE;

ADULT; BODY DYSMORPHIC DISORDER; CASE REPORT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; LETTER; OBSESSIVE COMPULSIVE DISORDER; REMISSION; SYMPTOM; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY IMAGE; DELUSIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE;

EID: 45149089353     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2008.01813.x     Document Type: Letter

References (4)

1. Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am. J. Psychiatry. 2005 162 : 1022 1023.
2. Phillips KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am. J. Psychiatry 2005 162 : 377 379.
3. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry 2000 61 : 514 517.
4. D'Amico G, Cedro C, Muscatello MR et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003 27 : 619 623.